Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in:

01-12-2024 | Biomarkers | editorial

KRAS: Finally a druggable target in oncology?

Author: Aysegul Ilhan-Mutlu, MD, PhD

Published in: memo - Magazine of European Medical Oncology | Issue 4/2024

Login to get access

Excerpt

After the initial establishment of microsatellite instability (MSI) as a tissue-agnostic biomarker, medical oncology is increasingly faced with other biomarkers that are assessed beyond tumor tissue type and have appropriate treatment options [1]. Although Kirsten rat sarcoma viral oncogene homologue (KRAS) was discovered as one of the first oncogenes, direct inhibition of the KRAS molecule has not yet been possible. Evaluating KRAS status helped us to implement upstream or downstream inhibitor molecules as this was considered a predictive biomarker [2]. …
Literature
1.
Gouda MA, Nelson BE, Buschhorn L, Wahida A, Subbiah V. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications. Clin. Cancer Res. 2023;29(15):2753–60.
2.
Garcia-Carbonero N, Martinez-Useros J, Li W, Orta A, Perez N, Carames C, et al. KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. Cells. 2020;9(1).
3.
4.
Schmitz K, Schatz C, Knabl L. KRAS in modern oncology – The Molecular Pathological point of view. memo. 2024;.
5.
Unraveling DB. (K)RAS in pancreatic ductal adenocarcinoma. memo. 2024;.
Metadata
Title
KRAS: Finally a druggable target in oncology?
Author
Aysegul Ilhan-Mutlu, MD, PhD
Publication date
01-12-2024
Publisher
Springer Vienna
Keyword
Biomarkers
Published in
memo - Magazine of European Medical Oncology / Issue 4/2024
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-024-01004-5

Other articles of this Issue 4/2024

CAR-T cell therapy for relapsed or refractory multiple myeloma in 2024—clinically available treatment options in Austria

Impact of the WHO-5 classification of haematolymphoid tumours on clinical practice

Unraveling (K)RAS in pancreatic ductal adenocarcinoma

  • Open Access
  • short review

Updates and changes in the treatment of cervical cancer

Recent developments in marginal zone lymphoma

KRAS (Kirsten rat sarcoma) in modern oncology—The molecular pathological point of view

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits